Cystic Fibrosis Treatment

View All

Is Bacteriophage a Potential Game-Changer in the Realm of Cystic Fibrosis Treatment?

Cystic Fibrosis impacts approximately 1 in every 3,500 births, with around 70,000 affected individuals globally, and 31,000 in the United States alone. Those with the condition experience the development of dense, adhesive mucus in their lungs, making them prone to infections. Over time, this leads to inflammation ...

Find More

Cystic Fibrosis Market | Vertex Pharmaceuticals
Cystic Fibrosis Market: A Rapidly Expanding Playing Field for Mid-Cap Pharma

Cystic Fibrosis is a rare inherited disorder that causes loss of lung function and damages the digestive system. It has a higher prevalence in the Caucasian population. For years there was no treatment available targeting the underlying cause, however, this changed in 2012 with the launch of Vertex Pharma’s Kalydec...

Find More